Deborah Schrag, MD, MPH, on Clinical Trial Design: Statistical Options and Challenges

First International Summit on Interventional Pharmacoeconomics

Deborah Schrag, MD, MPH, of Dana-Farber Cancer Institute, offers her perspective on near-equivalence, Bayesian noninferiority, and the value of cancer drug optimization.

Clinical Trial Design: Statistical Options/Challenges Panel Discussion

Daniel Goldstein, MD: Interventional Pharmacoeconomics - Why and How

Cody Peer, PhD, on Simulating Alternative Schedules for Checkpoint Inhibitors

Opportunities to Optimize Cancer Policies Panel Discussion

Garth Strohbehn, MD, MPhil, on Applied Clinical Pharmacology in a Crisis: Interventional Pharmacoeconomics and COVID-19

Jun

Today In Oncology

Deborah Schrag, MD, MPH, on Clinical Trial Design: Statistical Options and Challenges

Related Videos

Clinical Trial Design: Statistical Options/Challenges Panel Discussion

Daniel Goldstein, MD: Interventional Pharmacoeconomics - Why and How

Cody Peer, PhD, on Simulating Alternative Schedules for Checkpoint Inhibitors

Opportunities to Optimize Cancer Policies Panel Discussion

Garth Strohbehn, MD, MPhil, on Applied Clinical Pharmacology in a Crisis: Interventional Pharmacoeconomics and COVID-19

New Research Links Low Alcohol Consumption to Elevated Health Risks

Digital Tool May Improve Patient Engagement in Oncology Clinical Trials

GLP-1 RAs May Reduce Risk of Obesity-Related Cancers

Teclistamab in Previously Treated Multiple Myeloma

Addition of Talazoparib to Enzalutamide in Metastatic Androgen Pathway Modulation–Sensitive Prostate Cancer